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Rising Prevalence of Pneumocystis jirovecii 
Pneumonia Amongst the Non-HIV 
Immunosuppressed
Zachary Jones, MD and Anusha Ganesh, MD
InTroduCTIon
Fungal Pneumonia caused by Pnemocystis Jirovecci 
(PCP) has long been associated with morbidity and 
mortality in HIV-positive patients. With the widespread 
use of high dose corticosteroids and biologic therapies, 
the prevalence of PCP infection in the non-HIV immuno-
suppressed population has increased significantly. A lack 
of formalized prophylaxis guidelines in these specific 
populations has lead to increasing rates of preventable 
infection and death.
CaSE PrESEnTaTIon
The patient is a 63-year-old man, admitted to the 
hospital for persistent shortness of breath following 
a seven-day course of Levofloxacin taken as an 
outpatient. Two months prior, the patient was found by 
his hematologist to have a hemoglobin level of 5.5g/
dL, and was diagnosed with autoimmune hemolytic 
anemia.  He was started on a 12 week Prednisone taper 
following an initial blood transfusion.  Three weeks prior 
to admission, the patient began to develop shortness 
of breath worse with ambulation, a non-productive 
cough, and he denied fevers. At time of admission, the 
patient was taking Prednisone 40mg daily.
The patient’s past medical history was significant for 
Hodgkin’s Lymphoma in 2001 treated with Adriamycin, 
Bleomycin, Vinblastine and Dacarbazine (ABVD) and 
radiation therapy, with recurrence in the nasopharanx 
and lung requiring further ABVD cycles and left 
pneumonectomy in 2005. Patient also had renal cell 
carcinoma requiring nephrectomy in 2007. Social 
history was significant for a 5-year pack history of 
cigarette smoking. Family history was significant for 
myocardial infarction in his father at age 69. 
Vital signs at presentation were temperature of 99.4 F, 
blood pressure of 157/70, pulse of 105 beats per minute 
and oxygen saturation of 90% on room air. Pertinent 
positive physical exam findings were sinus tachycardia 
and diffuse wheezing in all right lung fields and lack 
of breath sounds on the left. Patient was resting 
comfortably and able to answer questions without 
distress. On admission, patient had a normal white 
blood cell count and a hemoglobin level of 9.8g/dL. 
Computed tomography scan of the thorax showed 
mild diffuse, nonspecific ground glass opacities. 
Figure 1. Cross Section CT scan with 
ground glass opacities, severe interlobar 
septal thickening likely related to interstitial 
pneumonia and stable postoperative 
changes following left pneumonectomy 
from day 1 of hospitalization.
Figure 2. Coronal Cut of CT scan demonstrating 
severe interstitial pneumonia cut from day 9 of 
hospitalization.
Figure 3. Sagittal cut from CT scan 
demonstrating interstitial pneumonia 
from day 9 of hospitalization.
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dIFFErEnTIal dIagnoSIS
The differential diagnoses for shortness of breath in this 
specific patient with previously treated hematologic 
malignancy currently on chronic steroids is vast, 
including pulmonary infection, Chronic Obstructive 
Pulmonary Disease (COPD), or volume overload. Also, 
two components of ABVD regimen can cause side 
effects producing symptoms of shortness of breath: 
Adriamycin can cause cardiomyopathy and subsequent 
congestive heart failure, and Bleomycin can cause 
pulmonary fibrosis. Further possible diagnoses include 
pulmonary embolism and opportunistic infection 
given his steroid use. 
ouTCoME 
The patient was initially started on Moxifloxacin 
and given Furosemide intravenously. The patient’s 
Ventilation/Perfusion scan was negative for embolism, 
echocardiogram revealed no systolic dysfunction, 
and HIV antibody, Antinuclear antibodies, perinuclear 
anti-neutrophil cytoplasmic antibodies (p-ANCA), 
cytoplasmic-ANCA (c-ANCA) and rheumatoid factor 
were negative. The patient’s respiratory viral and 
sputum culture were also negative. A right heart 
catheterization completed on day 6 of hospitalization 
revealed pulmonary hypertension. Bronchoscopy 
was performed on day 10 due to worsening hypoxia 
and worsening radiographic evidence of interstitial 
process on antibiotics and diuretics (Figure 1,2,3). 
Bronchoalveolar lavage demonstrated presence of 
Pneumocystis jirovecii.
The pat ient  was started on Tr imethopr im/
Sulfamethoxazole (Bactrim).  On day 15, the patient 
required continuous Bilevel Positive Airway Pressure 
(BIPAP) for worsening hypoxia and was transferred to 
the Intensive Care Unit. The patient was transitioned 
to intravenous Bactrim and his Prednisone dose was 
increased. On day 23, the patient required intubation 
and suffered pulseless electrical activity and return of 
spontaneous circulation was not achieved after 20 
minutes of cardiopulmonary resuscitation.
dISCuSSIon
Pneumocystis pneumonia (PCP) is a life threatening 
disease caused by the fungus Pneumocystis jirovecii 
previously classified as Pneumocystis carinii. While PCP 
is historically associated with HIV and CD4 counts less 
than 200/µL, there have been increasing case reports 
in HIV negative patients treated with high dose steroids, 
Methotrexate, Tacrolimus, Infliximab and Etanercept.1 In 
the HIV negative population, PCP has a higher likelihood 
of causing fulminant pulmonary disease more likely 
requiring mechanical ventilation.2 
In a study looking at those with Adult T Cell Leukemia 
treated with corticosteroids, there was a 16.6% overall 
risk of PCP infection without prophylaxis.3 In a small case 
series of patients with Giant Cell Arteritis treated with 
high dose Prednisone, 85% presented on admission 
solely with dyspnea, 43% required mechanical 
ventilation, and 29% died.4 The documented PCP 
mortality rate ranges from 51% - 80% in HIV negative 
patients.1 In a review of neurology literature, up to 
90% of patients were treated with high dose cortico-
steroids prior to diagnosis with PCP.6 In a Cochrane 
review of immunocompromised patients without HIV, 
thirteen trials showed a reduction of 85% in incidence 
of PCP when prophylaxis was administered.6 Across 
multiple specialties, no firm prophylaxis guidelines have 
been set. It is generally accepted that any patient on 
greater than or equal to Prednisone 20 mg per day for 
greater than 4 weeks should be considered for PCP 
prophylaxis with Bactrim. There was found to be no 
statistically significant difference when comparing once 
daily versus three times weekly dosing of Bactrim for 
prophylaxis.6
The diagnosis of PCP can be delayed due to nonspecific 
radiographic findings and vague symptoms at time of 
presentation, as seen with our patient who was not 
diagnosed until day 10 of hospitalization. Novel serologic 
markers that detect PCP have been described, with 
B-1,3 Glucan approaching 100% sensitivity but lacking 
specificity with regards to detecting PCP. Another 
marker, KL-6, is a glycoprotein elevated in interstitial 
pneumonitis caused by PCP, which is elevated in the 
HIV population, but has not been shown to reliably 
detect the disease in non-HIV patients.2 In the non-HIV 
immunosuppressed, the mainstay of diagnosis involves 
direct sampling via bronchoalveolar lavage and should 
be considered early in hospital stay for any patient at 
risk for PCP.
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Once a diagnosis is made, PCP treatment is similar 
regardless of reason for immunosuppression. Bactrim is 
the gold standard of therapy with Dapsone, Atovoquone, 
or Pentamidine used when Bactrim cannot be 
tolerated.7 Duration of treatment is not well established 
in non-HIV patients but should extend to at least 14 
days in contrast to the minimum of 21 days for the HIV 
positive. In patients with HIV and an A-a gradient greater 
than 35 mmHg or a PaO2 less than 70mmHg, cortico-
steroids should given. In contrast, adjunctive high dose 
corticosteroids increased mortality in the non-HIV 
immunocompromised and are not recommended.8 
KEy PoInTS
Pneumocystis pneumonia is a devastating disease of 
both HIV and non-HIV patients alike.  While there are no 
formalized guidelines, any patient on a corticosteroid 
dose greater or equal to Prednisone 20 mg per day 
for more than 4 weeks should be on prophylaxis. In 
doing so, the rates of PCP can be drastically lowered 
in these patient populations preventing undue burden 
of disease. 
Cartoon by Eugene Han, MD
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